Last reviewed · How we verify
Tocilizumab treatment
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.
At a glance
| Generic name | Tocilizumab treatment |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interleukin-6 is a cytokine that plays a key role in the inflammatory response. By blocking the interleukin-6 receptor, tocilizumab reduces inflammation and prevents tissue damage. This mechanism is particularly useful in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Giant cell arteritis
- Polyarticular juvenile idiopathic arthritis
- Systemic juvenile idiopathic arthritis
Common side effects
- Increased risk of infections
- Neutropenia
- Thrombocytopenia
- Hypersensitivity reactions
- Liver enzyme elevations
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Neutralizing Interleukin (IL)-6 (PHASE2)
- ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma (PHASE2)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |